Literature DB >> 24378990

Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity?

Constantina Andrada Treabă1, Rodica Bălaşa, Daniela Maria Podeanu, Iunius Paul Simu, Mircea Marian Buruian.   

Abstract

PURPOSE: We aimed to identify imaging characteristics on conventional magnetic resonance imaging that could predict multiple sclerosis (MS) brain lesion activity without contrast media administration.
MATERIALS AND METHODS: Magnetic resonance data sets of forty-two patients with relapsing-remitting MS who presented symptoms or signs suggestive of new disease activity were retrospectively reviewed. We classified the MS lesions into three types according to different patterns present on T2-weighted images and evaluated their relationship with the contrast uptake. Evolving aspects of each type of lesion were observed in 18 patients during a follow-up period ranging from nine to 36 months.
RESULTS: On T2-weighted images, only the pattern consisting of a thin border of decreased intensity compared with the lesion's center and perifocal edema (Type II) reached diagnostic accuracy in terms of its relationship with gadolinium enhancement (P = 0.006). The sensitivity was 0.461, and the specificity was 0.698. In contrast, enhancement was not significantly related to the pattern consisting of a lesion center that was homogeneously brighter than its periphery (Type I) or less-hyperintense T2 focal lesions with either homogeneous or inhomogeneous center (Type III) (P > 0.05 for both).
CONCLUSION: The assessment of MS lesion activity should include a careful evaluation of T2-weighted images in addition to contrast enhancement assessment. The presence of an accompanying peripheral thin rim of hypointensity on T2-weighted images related best with contrast enhancement and subsequent lesion activity and may represent an additional pattern for disease activity assessment when gadolinium examination is contraindicated or influenced by prior therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24378990      PMCID: PMC4463297          DOI: 10.5152/dir.2013.13313

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  29 in total

1.  Brain MR post-gadolinium contrast in multiple sclerosis: the role of magnetization transfer and image subtraction in detecting more enhancing lesions.

Authors:  M M Gavra; C Voumvourakis; A D Gouliamos; C Sfagos; L J Vlahos
Journal:  Neuroradiology       Date:  2004-02-19       Impact factor: 2.804

2.  The effectiveness of magnetization transfer technique in the evaluation of acute plaques in the central nervous system of multiple sclerosis patients and its correlation with the clinical findings.

Authors:  Köksal Atalay; Haldun Bariş Diren; Serkan Gelmez; Lütfi Incesu; Murat Terzi
Journal:  Diagn Interv Radiol       Date:  2005-09       Impact factor: 2.630

3.  MRI time series modeling of MS lesion development.

Authors:  Dominik S Meier; Charles R G Guttmann
Journal:  Neuroimage       Date:  2006-06-27       Impact factor: 6.556

Review 4.  MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system.

Authors:  Massimo Filippi; Maria Assunta Rocca
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

5.  Pattern of T2 hypointensity associated with ring-enhancing brain lesions can help to differentiate pathology.

Authors:  K M Schwartz; B J Erickson; C Lucchinetti
Journal:  Neuroradiology       Date:  2006-01-31       Impact factor: 2.804

6.  Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology.

Authors:  W Brück; A Bitsch; H Kolenda; Y Brück; M Stiefel; H Lassmann
Journal:  Ann Neurol       Date:  1997-11       Impact factor: 10.422

7.  Investigation of apparent diffusion coefficient and diffusion tensor anisotrophy in acute and chronic multiple sclerosis lesions.

Authors:  A L Tievsky; T Ptak; J Farkas
Journal:  AJNR Am J Neuroradiol       Date:  1999-09       Impact factor: 3.825

Review 8.  Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis.

Authors:  David H Miller
Journal:  NeuroRx       Date:  2004-04

Review 9.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Authors:  Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

Review 10.  Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis.

Authors:  C F Lucchinetti; W Brück; M Rodriguez; H Lassmann
Journal:  Brain Pathol       Date:  1996-07       Impact factor: 6.508

View more
  4 in total

1.  Quantitative MRI for Analysis of Active Multiple Sclerosis Lesions without Gadolinium-Based Contrast Agent.

Authors:  I Blystad; I Håkansson; A Tisell; J Ernerudh; Ö Smedby; P Lundberg; E-M Larsson
Journal:  AJNR Am J Neuroradiol       Date:  2015-10-15       Impact factor: 3.825

2.  Magnetic Susceptibility from Quantitative Susceptibility Mapping Can Differentiate New Enhancing from Nonenhancing Multiple Sclerosis Lesions without Gadolinium Injection.

Authors:  Y Zhang; S A Gauthier; A Gupta; L Tu; J Comunale; G C-Y Chiang; W Chen; C A Salustri; W Zhu; Y Wang
Journal:  AJNR Am J Neuroradiol       Date:  2016-06-30       Impact factor: 3.825

3.  Quantitative Susceptibility Mapping and R2* Measured Changes during White Matter Lesion Development in Multiple Sclerosis: Myelin Breakdown, Myelin Debris Degradation and Removal, and Iron Accumulation.

Authors:  Y Zhang; S A Gauthier; A Gupta; W Chen; J Comunale; G C-Y Chiang; D Zhou; G Askin; W Zhu; D Pitt; Y Wang
Journal:  AJNR Am J Neuroradiol       Date:  2016-06-02       Impact factor: 3.825

4.  Fluid-Attenuated Inversion Recovery Signal Intensity as a Predictor of Gadolinium Enhancement in Relapsing-Remitting Multiple Sclerosis.

Authors:  Mihail Guranda; Marco Essig; Ariane Poulin; Reza Vosoughi
Journal:  Int J MS Care       Date:  2018 Mar-Apr
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.